



**10th International Conference on Thrombosis & Hemostasis Issues in
Cancer (ICTHIC) – Virtual Edition
22 – 26 April 2021**

Program

Thursday 22nd 2021

15:00 – 15:15

Congress Opening: Anna Falanga, Benjamin Brenner, Alok Khorana

15:15 – 16:30

Special Session

COVID-19, cancer and thrombosis

Chairs: P. Gresele (Italy), A. Falanga (Italy)

Lecture: **COVID-19 Associated Thrombosis-a year later**
J. Connors (USA)

Lecture: **COVID-19 is an acquired vascular hemopathy**
D.M. Smadjia (France)

16:30 – 17:00

Special Lecture

Chair: A. Falanga (Italy)

Introduction to Lecture: *C. Rizzi (Italy)*

Lecture: **Are the new technologies useful to medicine or the opposite?**
A. Remuzzi (Italy)


Friday 23rd 2021

15:00 – 15:30

Plenary Lecture

6th Simon Karpatkin Memorial Lecture

Chairs: A. Falanga (Italy); B. Brenner (Israel); A.A. Khorana (USA)



10th International Conference on Thrombosis & Hemostasis Issues in Cancer

Introduction to Lecture: F.R. Rickles (USA)

Lecture: Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer - past, present and future

I. Pabinger (Austria)

15:30 – 17:00

Plenary Session 1

New Insights In Prevalence of Cancer-Associated Thrombosis

Chairs: H.A. Liebman (USA), M. Aapro (Switzerland)

PL-01 - Screening for Occult Cancer: Where Are We in 2020?

L. Jara-Palomares (Spain)

PL-02 - An overview of thrombotic complications of old and new anti-cancer drugs

M. Levi (The Netherlands)

PL-03 - Impact of arterial thrombosis in cancer patients

S.C. Cannegieter (The Netherlands)

PL-04 – Cancer associated thrombosis in pediatric setting

G. Kenet (Israel)

Selected Abstract

OC-01 - Incidence, Predictors and Clinical Outcomes of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Ductal Adenocarcinoma: Results of the Prospective BACAP-VTE Study

C. Frere, B. Bournet, S. Gourgou, J. Fraise, C. Canivet, J.M. Connors, L. Buscail, D. Farge, on behalf of the Groupe Francophone Thrombose et Cancer and the BACAP Consortium. (France, Canada)

OC-02 - Risk of venous thromboembolism in cancer patients: a cohort study

F. Mulder, E. Horváth-Puhó, N. van Es, H.W.M. van Laarhoven, L. Pedersen, H.R. Büller, H.T. Sørensen (The Netherlands, Denmark)

17:00 – 17:30

Roundtable

Risk assessment models for VTE in cancer

Chairs: P. Angchaisuksiri (Thailand), C. Ay (Austria)

Introduction: Overview of risk assessment models for VTE in ambulatory patients



10th International Conference on Thrombosis & Hemostasis Issues in Cancer

with cancer

G. Gerotziafas (France)

Discussants: N. Van Es (The Netherlands), A. Falanga (Italy), A.A. Khorana (USA), G. Gerotziafas (France), M.B. Donati (Italy)

Saturday 24th 2021

15:00 – 16:30

Plenary session 2

Hematological malignancies

Chairs: H. Ten Cate (The Netherlands), F. Rodeghiero (Italy)

PL-05- Risk-assessment of thrombosis and bleeding in hematological malignancies

B. Brenner (Israel)

PL-06 - Advances in management of coagulopathy in APL

M.A. Sanz (Spain)

PL-07 - Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia

A. Leader (Israel)

PL-08- Multiple myeloma-associated VTE risk prediction

K. Sanfilippo (USA)

Selected Abstract

OC-03 - The Molecular Mechanisms of Ponatinib-Induced Thrombosis

A.H. Schmaier, A.A. Merkulova, E.R. Chan, E.X. Stavrou, S.C. Mitchell, G.L. Forbes, P. Zeng (USA)

OC-04 - Differences in Thromboprophylaxis Between Hospitalized Patients with Solid or Hematological Malignancies

R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri (Spain)

16:30 – 17:00

Roundtable

Emerging practical guidelines for the prevention and treatment of CAT

Chairs: M. Cattaneo (Italy), R. Labianca (Italy)



10th International Conference on Thrombosis & Hemostasis Issues in Cancer

Introduction: Overview of VTE treatment and prevention in cancer according to clinical guidelines

G. Lyman (USA)

Discussant: A. Falanga (Italy), A. Lee (Canada), D. Farge (France), K. Jordan (Germany), I. Elalamy (France), G. Lyman (USA)

17:00 – 18:45

Plenary Session 3

Biomarkers in CAT and cancer progression

Chairs: N. Mackman (USA), A.K. Olsson (Sweden)

PL-09 - Impact of preclinical variables on thrombotic biomarkers levels in cancer

R. Selby (Canada)

PL-10 - Biomarkers in cancer VTE: Data from the AVERT study

N. Key (USA)

PL-11 - Thrombotic biomarkers in occult cancer and cancer risk prediction

M. Marchetti (Italy)

PL-12 - Genes and proteins associated with CAT risk

H. Versteeg (The Netherlands)

PL-13 - Role of NETs in cancer associated-thrombosis

S. Zeerleder (Switzerland)

Selected Abstract

OC-05 - Biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis (HISPALIS- Study).

R. Otero Candelera, V. Sánchez López, E. Arellano Orden, J. Oto Martinez, A. Solier-López, S. Marín Romero, L. Jara Palomares, T. Elias Hernández, M.I. Asencio Cruz, I. Blasco-Esquivias, M. Rodriguez de la Borbolla, J.M. Sánchez Díaz, F.J. Rodriguez Martorell, P. Medina Badenes (Spain)

OC-06 - Proteomic profiling in cancer-associated VTE

M. Panova-Noeva, A. Schulz, T. Köck, V. ten Cate, B. Wagner, S. Rapp, M. Lenz, A. Zink, M. Ghadessi, S. Konstantinides, H. ten Cate, S. Heitmeier, P. Wild (Germany, The Netherlands)

Sunday 25th 2021

15:00 – 16:45

Plenary Session 4

Bench to Bedside: New insights Into Hemostasis and Cancer

Chairs: P.M. Sandset (Norway), R. Giavazzi (Italy)

PL-14 - Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations

J. Rak (Canada)

PL-15 - Coagulation signaling and cancer immuno-therapy

W. Ruf (Germany)

PL-16 - Heparanase-revisited

Y. Nadir (Israel)

PL-17 - Mouse model of thrombosis and cancer

C. Dubois (France)

PL-18 - The thrombin-inflammation axis in cancer progression

J. Palumbo (USA)

Selected Abstract

OC-07 - Thrombin Tips the Scales towards Effective Immune Checkpoint Blockade in Cancer

R. Cantrell, L. Rosenfeldt, D. Mureb, M. Lehn, B.K. Sharma, A. Revenko, B. Monia, E. Janssen, J.S. Palumbo (USA)

OC-08 - Plasminogen activator inhibitor 1 and venous thrombosis in nude mice bearing human pancreatic tumors

Y. Hisada, A. Maqsood, K. B. Garratt, B. C. Cooley, N. Mackman (USA)

16:45 – 17:15


Debate

Outpatient prophylaxis: are we there yet?

Chairs: G. Agnelli (Italy), C. Francis (USA)

NO: F. Klok (The Netherlands)

YES: A.A. Khorana (USA)



10th International Conference on Thrombosis & Hemostasis Issues in Cancer

17:15 – 18:30

Plenary Session 5

Prevention of VTE in cancer patients

Chairs: P. Prandoni (Italy), J.A. Paramo (Spain)

PL-19 - Inpatient thromboprophylaxis in cancer patients: what is the evidence?

J Zwicker (USA)

PL-20 - Roles of LMWH for prevention in cancer patients

A Maraveyas (UK)

PL-21 - Meta-analysis and systematic review of NOAC prophylaxis in high risk cancer outpatients

N. Kuderer (USA)

Selected Abstract

OC-09 - D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial

S. Vadhan-Raj, N. Kuderer, T. Wun, J. Patel, K. McCrae, X. Zhou, U. Vijapurkar, C.V. Damaraju, P. Wildgoose, G. Lyman, A.A. Khorana (USA)

OC-10 - A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

A. Muñoz, C. Ay, E. Grilz, S. López, C. Font, V. Pachón, V. Castellón, V. Martínez-Marín, M. Salgado, E. Martínez, J. Calzas, A. Rupérez, E. Salas, I. Pabinger, J.M. Soria (Spain, Austria)

Monday 26th 2021

15:00 – 16:40


Plenary Session 6

Evolving Data for Treatment of VTE in cancer

Chairs: G. Sof (USA), W. Ageno (Italy)

PL-22 - Anticoagulation in Cancer Patients: advantages and disadvantages

A.J. Munoz (Spain)



10th International Conference on Thrombosis & Hemostasis Issues in Cancer

PL-23 - VTE management: emerging insights from the GARFIELD VTE registry

A.J. Kakkar (UK)

PL-24 - Treatment of VTE in cancer patients: from clinical trials to real life

G. Agnelli (Italy)

PL-25 - VTE in Palliative Care Patients: What do we know?

S. Noble (UK)

Selected Abstract

OC-11 - Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study

F.T.M. Bosch, T.F. Wang, M. Di Nisio, A. Segers, J. Connors, D. Garcia, F.I. Mulder^{1,2}, J. Weitz, H.R. Büller, M. Carrier, P. Verhamme, M. Grosso, G. Raskob, N. van Es (The Netherlands, USA)

OC-12 - Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study

F.X. Lapébie, A. Bura-Rivière, A. Merah, L. Bertoletti, M. Monreal, RIETE investigators (France, Spain)

OC-13 - Apixaban as treatment for cancer-associated venous thrombosis - The CAP study

T.L. Hannevik, J. Brekke, T. Enden, H. Frøen, H. Garresori, W. Ghanima, E.M. Jacobsen, P.Q. Paulsen, A.C. Porojnicu, A.H. Ree, P.M. Sandset, D. Torfoss, E.O. Velle, H.S. Wik, A.E.A. Dahm (Norway)

OC-14 - Rivaroxaban versus Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism: the CASTA DIVA Trial

Guy Meyer, Philippe Girard, Laurent Bertoletti, Anais Charles Nelson, Silvy Laporte, Isabelle Mahé, Olivier Sanchez, Patrick Mismetti, on behalf the CASTA DIVA Investigators (France)

16:40 – 17:10

Debate

Incidental VTE: To treat or not to treat?

Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands)

YES: M. Di Nisio (Italy)

10th International Conference on Thrombosis & Hemostasis Issues in Cancer

NO: M. Carrier (Canada)

17:10 – 17:25

Concluding Remarks

Auspices



Società Italiana di
Ematologia (SIE)



ASSOCIAZIONE ITALIANA
DONNE MEDICO



AIMM Sezione di Bergamo



IsthTM
International Society on
Thrombosis and Haemostasis

